Actelion announces changes to its executive team

15-Jun-2017 - Switzerland

Actelion Ltd announced changes to its executive team that will take effect upon the settlement of the public tender offer by Johnson & Johnson's Swiss subsidiary, Janssen Holding GmbH, for all publicly held shares of Actelion which is expected to occur on 16 June 2017 (Settlement).

As previously announced, Jane Griffiths will assume the position as Actelion's Global Head and Otto Schwarz will retire from his position as Chief Operating Officer upon Settlement. Jean-Paul Clozel, CEO, André C. Muller, CFO, and Guy Braunstein, Head of Global Clinical Development, will leave Actelion's executive committee, which will be dissolved as of Settlement, and move to Idorsia Ltd on 16 June 2017. Jane Griffiths will be supported in her top executive role at Actelion by a newly formed leadership team. Nicholas Franco, who has been the Chief Business Development Officer, will be a member of this leadership team going forward.

Other news from the department people

More news from our other portals

So close that even
molecules turn red...